Thanks Brentie,

I will be watching. MannKind remains very speculative until financing is clarified. I do not expect partnership before trial results but would be pleasantly surprised if it happened. If the company is in fact discussing this drug with multiple big pharmas, it is quite possible somebody might blink. Nothing happens in the biotech space without others knowing about it.

Out of all the things we could be attempting to prove, bioavailability results should be the easiest thing to show with the new inhaler. Multiple trials have shown zero safety flags. It appears the company is proceding carefully during the enlistment phase of the studies to ensure good results.

Financing secured, positive trial results, partnership. I would enjoy a prolonged 24 month squeeze on people who thought shorting in the $1.50- $2.00 range was a good idea.